Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Study of Recombinant Interferon Alpha and Etoposide in Patients With Relapsed Osteosarcoma.

Next Previous
X
Search
Trial Profile

Phase II Study of Recombinant Interferon Alpha and Etoposide in Patients With Relapsed Osteosarcoma.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 06 Aug 2012

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Etoposide phosphate (Primary) ; Interferon alpha-2a (Primary)
  • Indications Osteosarcoma
  • Focus Therapeutic Use

    • Most Recent Events

    • 27 May 2009 Actual end date (1 Mar 2009) and additional lead trial centre added as reported by ClinicalTrials.gov record.
    • 27 May 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 14 Jan 2008 The expected completion date for this trial is now 1 Nov 2008.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top